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TRICK2, a new alternatively spliced receptor that transduces the
cytotoxic signal from TRAIL
Gavin R. Screaton, Juthathip Mongkolsapaya, Xiao-Ning Xu, Alison E. Cowper,
Andrew J. McMichael and John I. Bell
A subset of the tumour necrosis factor (TNF) receptor
family contain a conserved intracellular motif, the death
domain. Engagement of these receptors by their
respective ligands initiates a signalling cascade that
rapidly leads to cell death by apoptosis. We have
cloned a new member of this family, TRICK2, the TRAIL
(TNF-related apoptosis-inducing ligand) receptor
inducer of cell killing 2. TRICK2 is expressed in a
number of cell types, and to particularly high levels in
lymphocytes and spleen. Two isoforms of the TRICK2
mRNA are generated by alternative pre-mRNA splicing
and differ by a 29 amino-acid extension to the
extracellular domain. Overexpression of TRICK2 rapidly
induced apoptosis in 293T cells; this induction was
dependent upon the presence of the death domain of
TRICK2. Using a soluble molecule containing the
TRICK2 extracellular domain, we demonstrated that
TRICK2, like DR4 [1], is a receptor for TRAIL/APO-2L
[2,3] and could inhibit TRAIL-induced killing of
lymphocyte lines, such as the Jurkat T-cell line. TRAIL is
upregulated upon lymphocyte activation, as is the
intensively studied ligand for Fas, FasL [4]. TRAIL and
its receptors might therefore provide another system
for the regulation of lymphocyte selection and
proliferation, as well as providing an additional weapon
in the armoury of cytotoxic lymphocytes.
Address: Molecular Immunology Group, Institute of Molecular
Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Correspondence: Gavin R Screaton
Received: 2 July 1997
Revised: 1 August 1997
Accepted: 1 August 1997
Current Biology 1997, 7:693–696
http://biomednet.com/elecref/0960982200700693
© Current Biology Ltd ISSN 0960-9822
Results and discussion
Cloning of TRICK2 
The expressed sequence tag subset of the National
Centre for Biotechnological Information database was
screened for homology to the cysteine-rich extracellular
domain of the TNF receptor family and also for a degen-
erate death-domain sequence. Several novel sequences
were identified, allowing oligonucleotide primers to be
designed so as to amplify the coding region of TRICK2.
The predicted amino-acid sequence of TRICK2 is shown
in Figure 1a. TRICK2 is a type I membrane protein with a
43 amino-acid signal sequence and the mature protein has
a predicted molecular mass of 43.4 kDa. The extracellular
domain has 58% amino-acid identity to DR4 and encodes
one partial and two complete nerve growth factor receptor
(NGFR) repeats. Following a 27 amino-acid transmem-
brane domain, TRICK2 has a 203 amino-acid intracellular
domain. A clear carboxy-terminal death domain was iden-
tified in TRICK2 and is aligned with the death domains of
other proteins in Figure 1b. The death domain of TRICK2
has 30, 19, 31 and 65% identity to the death domains of
the TNF receptor TNF-R1, Fas, LARD (lymphocyte-
associated receptor of death) and DR4, respectively.
Cysteine-rich NGFR repeats are common to all TNF
receptor family members, but the number of repeats
varies, there being four in TNF-R1 and LARD/DR3/
Wsl1/APO-3/TRAMP [5–9], three in Fas and only two in
DR4, TRICK2 and the chicken death receptor CAR1 [10].
The TRICK2/DR4 NGFR repeats show homology to
repeats 2 and 3 of the TNF receptor, consistent with the
crystal structure of the TNFβ–TNF-R1 complex which
revealed that the interaction surface on TNF-R1 contains
residues in repeats 2 and 3 [11]. The occurrence and func-
tional integrity of these two-domain receptors raises the
question as to the function of the additional repeats found
in other members of the TNF receptor family. It has been
proposed that the first repeat of TNF-R1 could promote
dimerisation of the receptor, which might not initiate a sig-
nalling pathway, and would therefore protect the cell from
apoptosis in the absence of TNF [12]. 
Expression and alternative splicing of TRICK2
Northern blot analysis using TRICK2 cDNA as a probe
revealed that a 4.5 kb mRNA was expressed in most tissues
(thymus, prostate, testis, ovary, small intestine, colon, heart,
placenta, lung, liver, skeletal muscle and kidney). Expres-
sion was particularly high in peripheral blood lymphocytes
(PBLs), pancreas and heart, but was absent from brain (data
not shown). After a longer exposure of the blot, an addi-
tional band at around 6.5 kb was visualised in many of the
samples. As TRICK2 is expressed at high levels in PBLs
and spleen, we examined its expression following lympho-
cyte activation. After 3 days’ treatment of PBLs with phy-
tohaemagglutinin (PHA), the expression of TRICK2 did
not appear to change, but notably the expression of TRAIL
increased markedly from almost undetectable levels in the
resting state (Figure 2a). The upregulation of TRAIL
mimics the upregulation of Fas ligand (FasL) seen after
lymphocyte activation and might have consequences
for the survival of activated cells. In this respect, it has
been shown that APO-2L/TRAIL causes apoptosis in
interleukin-2-stimulated T lymphocytes [13].
We identified two TRICK2 isoforms,
TRICK2a and TRICK2b, which are
expressed in a variety of tissues.
TRICK2b has an 87 base-pair inser-
tion compared with TRICK2a, result-
ing in an in-frame insertion of 29
amino acids. Alignment of the
TRICK2 isoforms with DR4 revealed
that DR4 does not contain this
inserted sequence and is therefore
similar in structure to TRICK2a. The
inserted sequence may represent a
retained intron as it has flanking
sequences that match consensus 
5′ and 3′ splice sites. In contrast to
LARD [5], the ratio of
TRICK2a : TRICK2b did not change
upon T-cell activation, although a dif-
ference in the ratios of these two
forms was found in a survey of lym-
phocyte tumour cell lines (Figure 2b,
compare CEM with Jurkat). The
expression of two isoforms of
TRICK2 that have different spacings
between the transmembrane domain
and the TRAIL-binding domain
might regulate the response to
TRAIL. The reason for the apparent
functional redundancy in the TRAIL
system, in which there are two recep-
tors for one ligand, is not clear. TNF
has two receptors, but only one of
these, TNF-R1 has a death domain. It
will be interesting to study whether a
complex formed by the binding of two or three different
receptors — DR4, TRICK2a and TRICK2b — to a
TRAIL trimer can signal death.
694 Current Biology, Vol 7 No 9
Figure 1
(a) Predicted amino-acid sequence of
TRICK2b showing the predicted leader
sequence (Leader), NGFR repeats (NGFRI
and II), the region absent in the alternatively
spliced clone TRICK2a (Alt. Splice),
transmembrane domain (TM) and death
domain. Genbank accession numbers:
TRICK2a AF018657; TRICK2b AF018658.
(b) Alignment of the death-domain sequences
of a variety of death-domain-containing
proteins. Shaded letters indicate conserved
amino-acid residues.
Figure 2
(a) RT-PCR amplification of TRICK2, DR4
and TRAIL from RNA from resting PBLs and
PHA blast PBLs; the control samples
contained no cDNA in the PCR step. (b)
RNA from a range of cell lines was subjected
to RT-PCR analysis across the alternatively
spliced region of TRICK2, yielding products
of 262 bp for TRICK2b and 175 bp for
TRICK2a. The lower panel shows
amplification using control GAPDH primers.
RNA (10 µg) was used in an oligo-dT-primed
cDNA synthesis reaction driven by avian
myeloblastosis virus reverse transcriptase:
10% of this reaction was then amplified by
PCR for 30 cycles with primers specific for
the extracellular domains of TRICK2, DR4
and TRAIL.
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Overexpression of TRICK2 leads to apoptosis
Overexpression of death-domain-containing molecules
leads to apoptosis in the absence of their cognate ligands
[14]. This effect presumably represents inappropriate
aggregation of the overexpressed receptor which then
recruits the intracellular death adaptor molecules leading
to activation of the death pathway. TRICK2 was co-
transfected with a β-galactosidase reporter plasmid into
COS cells, and apoptosis was scored on the basis of cellu-
lar morphology: healthy cells correspond to those with
several long pseudopodia whereas cells undergoing
apoptosis round up and subsequently detach from the
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Effect of TRICK2 upon cell viability. COS cells cotransfected with a
β-galactosidase plasmid plus (a) control plasmid (pCDNA3-
Invitrogen), or (b) full-length TRICK2. The TRICK2-expressing blue
cells show the typical features of apoptosis and round up compared to
the cells transfected with the control plasmid. (c) Cells were counted
24 h after transfection and round blue cells were expressed as a
percentage of total blue cells [15]. This figure is representative of five
separate experiments in COS-1 or 293T cells, which gave equivalent
results. TRICK2b was amplified using Pfu polymerase (Stratagene)
and the primers F TRICK2 Kpn AGCTCGGTACCCCAACAAGACCT
AGCTCCCCAG and R TRICK2 Not GAGTCCGCGGCCGCACTTTC
CTACTGACTGGAGTCC, and following digestion with KpnI and NotI
TRICK2b was cloned into the expression vector pCD33L which
contains the CD33 leader sequence [5]. Primer pair F TRICK2 Kpn
(above) and R TRICK2 Eco GCAGAATTCTTACTTCCACAGTAAAGA
CTTGCAAAC were used to clone the extracellular and transmembrane
domains of TRICK2 into pCD33L. COS-1 and 293T cells were grown
to 25% confluence in 6-well tissue culture plates and cotransfected
with 0.25 µg pcDNA 3.1Myc-His/lacZ (Invitrogen) and 2 µg of the
indicated second plasmid using calcium phosphate precipitation. Cells
were fixed 24 h after transfection, stained with X-Gal and 100 cells
from each well were counted.
Figure 4
Soluble TRICK2 inhibits TRAIL-mediated killing
of Jurkat cells (a) The entire coding region of
TRAIL was amplified from PHA blast PBL
cDNA and cloned into pcDNA3. Then, 293T
cells were cotransfected by calcium-phosphate
precipitation with pcDNA3 TRAIL (40 µg per
15 cm plate) and a second plasmid containing
the CD8α cDNA (10 µg per plate). Cells were
lifted with PBS containing 3 mM EDTA 48 h
after transfection, and cotransfected cells were
isolated using anti-CD8 coated magnetic
beads (DYNAL). Cells (105 per well) were
seeded into 96-well plates and then mixed with
51Cr-labelled Jurkat T cells (104) in the
presence or absence of 20 µg/ml soluble
fusion proteins comprising the extracellular
domains of the receptors fused to the constant
Fc domain of the IgG1 heavy chain.
Background release was calculated by
culturing the Jurkat cells in medium alone,
RPMI supplemented with 10% foetal calf
serum, or with CD8-purified 293T cells that
had not been cotransfected with TRAIL.
Supernatants were harvested 12–16 h later
and 51Cr release counted by scintillation on a
beta-plate counter. The extracellular domains of
Fas (amino acids 17–173), LARD (amino acids
25–200), TNF-R1 (amino acids 24–210), DR4
(amino acids 104–217) and TRICK2 (amino
acids 57–183) were cloned to create a fusion
with the CD5 leader and the Fc domain of
IgG1. Recombinant protein was produced in
293T cells and purified using protein
A–sepharose. (b) Soluble TRICK2 binds to
TRAIL-transfected 293T cells.The cells were
cotransfected with CD8 plus either TRAIL or
an empty vector control plasmid. Cells were
then incubated with a biotinylated TRICK2–Fc
fusion protein and counterstained with
phycoerythrin-conjugated streptavidin.
Fluoroscein isothiocyanate-conjugated anti-
CD8 antibody was used to detect and set a
gate for the cotransfected cells as shown in
the histogram.
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monolayer [15]. Most cells transfected with the full-length
receptor manifested the characteristic morphological
changes associated with apoptosis (Figure 3a,b); the quan-
tification of these results is shown in Figure 3c. Transfec-
tion with the empty vector, or with a deletion mutant of
TRICK2 lacking the cytoplasmic domain (TRICK2∆DD)
did not lead to apoptosis; however, transfection with
LARD or DR4 gave comparable results to TRICK2.
TRICK2 is a receptor for TRAIL
To examine whether TRICK2 is a receptor for TRAIL, a
bioassay using TRAIL-mediated cytotoxicity was devel-
oped. This assay is similar to that commonly used to study
FasL activity [16]. The targets in this assay were 51Cr-
labelled Jurkat T cells; by RT-PCR analysis, Jurkat cells
were found to express both TRICK2 and DR4 (data not
shown). The labelled cells were incubated for 12 hours
with 293T cells that had been transfected with TRAIL and
51Cr release was monitored in the supernatants by scintilla-
tion. We produced soluble fusion proteins comprising the
extracellular domains of the death receptors TNF-R1, Fas,
LARD, DR4 and TRICK2 and the immunoglobulin G1 Fc
constant regions. The ability of these proteins to block
TRAIL-mediated cytotoxicity was then tested in the bioas-
say. As expected, soluble TNF-R1, Fas and LARD had no
inhibitory effect (Figure 4a). We observed a partial block to
TRAIL cytotoxicity by DR4 and almost 100% inhibition by
the TRICK2–Fc fusion protein, demonstrating that
TRICK2 is a receptor for TRAIL. To confirm that TRICK2
is a TRAIL receptor, we stained cells with biotinylated
TRICK2–Fc. TRICK2 stained TRAIL-transfected but not
control cells (Figure 4b). 
FasL has assumed a prominent role in the function and
control of the immune system. The induction of FasL
upon lymphocyte activation has two opposing effects: the
augmentation of cytotoxic T-cell activity and the exposure
of activated cells to the danger of apoptosis [4]. Mice defi-
cient in both perforin and Fas expression still show some
cytotoxic T-cell activity at 20 hours implying that other
cytotoxic pathways, possibly including those induced by
TNF, remain intact [17]. TRAIL is expressed at low levels
on T cells and we have shown here that it is induced upon
lymphocyte activation. This expression is similar to that of
FasL and suggests that the TRAIL/DR4/TRICK2 system
has the potential to play an auxiliary role to that of
FasL/Fas in lymphocyte cytotoxicity and homeostasis. 
Aberrant FasL expression occurs in a number of disease
processes, such as HIV and malignant tumours. The
expression of FasL by the infected or neoplastic cells
might deliver a death signal to cytotoxic T cells expressing
Fas [18,19]. This process would protect the target cells
from cytotoxic T lymphocytes and allow their escape from
immune surveillance. DR4 and TRICK2 are co-expressed
in PBLs and lymphocyte cell lines, which are exquisitely
sensitive to TRAIL-mediated cytotoxicity [2]. It is there-
fore possible that, as for FasL, inappropriate expression of
TRAIL could protect cells from immune attack.
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